 Home > Active Ingredient News > Drugs Articles > Too big to succeed? The return of 100 billion market capitalization pharmaceutical companies is not as good as that of the S&P 500

Too big to succeed? The return of 100 billion market capitalization pharmaceutical companies is not as good as that of the S&P 500

 Last Update: 2022-01-26
 Source: Internet
 Author: User

Tags

triumeq drug

drug act

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

news

Today, an investor named Maxx Chatsko analyzed the total investment return (share value + dividends) of 18 pharmaceutical companies with a market value of more than $100 billion from reaching this market value to last September
.

Compared with the S&P 500 index, except for Johnson & Johnson, Novo Nordisk, and Moderna, the total investment return after becoming a billion-dollar giant is not as good as that of the S&P.

Drug source analysis

Why the return on investment of such a highly innovative and socially important sector as a leading pharmaceutical company is so unbearable
.

The first is volume.

The more important question is how did the pharmaceutical company reach the market value of 100 billion yuan
.

Unlike McDonald's, which sells more than 2 billion hamburgers every year, drug companies usually only rely on the emergence of a few important products to become a Big Mac

Unlike the situation where burgers will always be sought after by foodies, drugs have a life cycle
.

Patents are a key factor, especially for small-molecule drugs, whose value will drop significantly after the patent expires

This data also shows that even top pharmaceutical companies are unable to fight back in the face of the complexity of new drug discovery, and more sustainable discovery of blockbuster drugs is the only way for high-tech giant pharmaceutical companies to beat burger restaurants
.

Now multiple technology platforms such as gene editing, gene therapy, RNAi, mRNA, protein degradation, etc.

Original link: https://7investing.

Original link: https://7investing.
com/articles/why-are-100-billion-drug-developers-such-lousy-investments/

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Best price Pure Tirzepatide powder 10mg vial Tirzepatide CAS 2023788-19-2 ouda

CAS No.: 2023788-19-2

Pharmacy Grade

$40.00/G FOB

hot sale, factory price, Weight loss, Retalutide 2mg 5mg 10mg 20mg

CAS No.: 2381089-83-2

Pharmacy Grade

$110-120/UNIT FOB

High Quality Pure N-Isopropylbenzylamine Bar Crystal N Isopropylbenzylamine

CAS No.: 102-97-6

Pharmacy Grade

$650-700/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.